Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.
New drug therapies to treat hepatitis C (HCV) and HIV infection are being developed with improved understanding of the molecular structures of the viruses themselves, the pathogenesis of infection and the specific immune responses needed to eradicate or control these infections. Interferon and ribavirin based therapies will continue to be a component of HCV therapy for the near future combined with other novel compounds directed at targets of viral replication, immunomodulation or cell entry. The goals of anti-HCV therapy are viral eradication for differing genotypes and prevention of hepatic morbidity such as hepatocellular carcinoma and cirrhosis. Future antiretroviral therapies for HIV will include agents that focus on new classes of inhibitors of viral replication and cell binding. The new treatment choices in HIV will need to ensure effective and durable viral suppression especially against highly resistant virus strains, regimen tolerability and improved toxicity.
Tedaldi
Ellen M
EM
Temple Comprehensive HIV Program, Temple University Hospital, 1316 West Ontario Street, Philadelphia, PA 19140, USA. etedaldi@temple.edu
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D011741:Pyrimidine Nucleosides / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D015819:Substance Abuse, Intravenous / Q000453:epidemiology*
D044966:Anti-Retroviral Agents; D000998:Antiviral Agents; D011741:Pyrimidine Nucleosides; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; C509700:elvitegravir; C506207:valopicitabine